Apocrine metaplasia of breast cancer: Clinicopathological features and predicting response

Breast Cancer

Volumn 17, Issue 4, 2010, Pages 290-297

  Ogiya, Akiko ^a   Horii, Rie ^b   Osako, Tomo ^b   Ito, Yoshinori ^b   Iwase, Takuji ^b   Eishi, Yoshinobu ^c   Akiyama, Futoshi ^a  

^a CANCER CHEMOTHERAPY CENTER   (Japan)

^b CANCER INSTITUTE HOSPITAL   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

Author keywords

Apocrine metaplasia; Breast cancer; Chemotherapy; Predictive marker

Indexed keywords

ANDROGEN RECEPTOR; CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; METHOTREXATE; PROGESTERONE RECEPTOR; PROTEIN BCL 2; TAMOXIFEN;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER THERAPY; CELL GRANULE; CLINICAL FEATURE; CYTOPLASM; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; JAPANESE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; METAPLASIA; MULTIVARIATE ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; SCORING SYSTEM; SURVIVAL RATE;

ADULT; AGED; AGED, 80 AND OVER; APOCRINE GLANDS; BIOLOGICAL MARKERS; BREAST NEOPLASMS; CARRIER PROTEINS; DISEASE-FREE SURVIVAL; FEMALE; GLYCOPROTEINS; HUMANS; KI-67 ANTIGEN; METAPLASIA; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR, ERBB-2; RECEPTORS, ANDROGEN; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 77958096995     PISSN: 13406868     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12282-009-0178-9     Document Type: Article

References (28)

1. FP O'Malley A Bane 2008 An update on apocrine lesions of the breast Histopathology 52 3 10 10.1111/j.1365-2559.2007.02888.x 18171412 (Pubitemid 350265178)
2. H Takeuchi K Tsuji H Ueo T Kano Y Maehara 2004 Clinicopathological feature and long-term prognosis of apocrine carcinoma of the breast in Japanese women Breast Cancer Res Treat 88 49 54 10.1007/s10549-004-9495-z 15538045 (Pubitemid 39524444)
3. JR Durham RE Fechner 2000 The histologic spectrum of apocrine lesions of the breast Am J Clin Pathol 113 S3 S18 1:STN:280:DC%2BD383lsVyjsg%3D%3D 11993707
4. Tavassoli FA, Devilee P, World Health Organization Classification of Tumours. Pathology and genetics of tumours of the breast and female genital organs. Lyon: IARC Press;2003.
5. Rosen PP. Apocrine carcinoma. In: Weinberg RW, Donnellan K, Palumbo R, editors. Rosen's breast pathology. 2nd ed. Philadelphia: Lippincott Williams & Wilkins;2001. p. 483-95.
6. Azzoparidi JG. Problems in breast pathology. Major problems in pathology. vol. 11. London: W.B. Saunders;1979.
7. V Eusebi RR Millis MG Cattani G Bussolati JG Azzopardi 1986 Apocrine carcinoma of the breast. A morphologic and immunocytochemical study Am J Pathol 123 532 541 1:STN:280:DyaL283jvFGntA%3D%3D 3717305
8. JA Mossler TK Barton AD Brinkhous KS McCarty JA Moylan KS McCarty Jr 1980 Apocrine differentiation in human mammary carcinoma Cancer 46 2463 2471 1:STN:280:DyaL3M%2FmsVaksg%3D%3D 10.1002/1097-0142(19801201)46:11<2463::AID- CNCR2820461127>3.0.CO;2-# 6254632
9. Haagensen CD. Diseases of the breast. 3rd ed. Philadelphia: W.B. Saunders;1986.
10. WR Miller J Telford JM Dixon AA Shivas 1985 Androgen metabolism and apocrine differentiation in human breast cancer Breast Cancer Res Treat 5 67 73 1:CAS:528:DyaL2MXhsl2hu74%3D 10.1007/BF01807652 3978248 (Pubitemid 15163220)
11. D Faratian J Bartlett 2008 Predictive markers in breast cancer-the future Histopathology 52 91 98 1:STN:280:DC%2BD1c%2FgsF2msQ%3D%3D 10.1111/j.1365-2559. 2007.02896.x 18171420 (Pubitemid 350265186)
12. IF Faneyte JG Schrama JL Peterse PL Remijnse S Rodenhuis MJ van de Vijver 2003 Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome Br J Cancer 88 406 412 1:STN:280:DC%2BD3s%2FlvVChtA%3D%3D 10.1038/sj.bjc.6600749 12569384 (Pubitemid 36308152)
13. H Fiegl A Jones C Hauser-Kronberger G Hutarew R Reitsamer RL Jones M Dowsett E Mueller-Holzner G Windbichler G Daxenbichler G Goebel C Ensinger I Jacobs M Widschwendter 2008 Methylated NEUROD1 promoter is a marker for chemosensitivity in breast cancer Clin Cancer Res 14 3494 3502 1:CAS:528:DC%2BD1cXmslygtro%3D 10.1158/1078-0432.CCR-07-4557 18519782
14. MT Sandri HA Johansson L Zorzino M Salvatici R Passerini P Maisonneuve A Rocca G Peruzzotti M Colleoni 2007 Serum EGFR and serum HER-2/neu are useful predictive and prognostic markers in metastatic breast cancer patients treated with metronomic chemotherapy Cancer 110 509 517 1:CAS:528:DC%2BD2sXpt1yqu78%3D 10.1002/cncr.22825 17559147 (Pubitemid 47106138)
15. A Di Leo M Tanner C Desmedt M Paesmans F Cardoso V Durbecq S Chan T Perren M Aapro C Sotiriou MJ Piccart D Larsimont Isola J TAX 303 Translational Study Team 2007 p-53 Gene mutations as a predictive marker in a population of advanced breast cancer patients randomly treated with doxorubicin or docetaxel in the context of a phase III clinical trial Ann Oncol 18 997 1003 1:STN:280:DC%2BD2szntVWgtw%3D%3D 10.1093/annonc/mdm075 17369602 (Pubitemid 47050490)
16. R Horii F Akiyama Y Ito M Matsuura Y Miki T Iwase 2007 Histological features of breast cancer, highly sensitive to chemotherapy Breast Cancer 14 393 400 10.2325/jbcs.14.393 17986805
17. W Ichikawa T Takahashi K Suto Y Shirota Z Nihei M Shimizu Y Sasaki R Hirayama 2006 Simple combinations of 5-FU pathway genes predict the outcome of metastatic gastric cancer patients treated by S-1 Int J Cancer 119 1927 1933 1:CAS:528:DC%2BD28Xps1Snsbo%3D 10.1002/ijc.22080 16736497 (Pubitemid 44356853)
18. C Aschele S Lonardi S Monfardini 2002 Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer Cancer Treat Rev 28 27 47 1:CAS:528: DC%2BD38XlsVeisbk%3D 10.1053/ctrv.2002.0253 12027413 (Pubitemid 34679207)
19. A Moliterni S Ménard P Valagussa E Biganzoli P Boracchi A Balsari P Casalini G Tomasic E Marubini S Pilotti G Bonadonna 2003 HER2 overexpression and doxorubicin in adjuvant chemotherapy for resectable breast cancer J Clin Oncol 21 458 462 1:CAS:528:DC%2BD2cXpsVGrtLo%3D 10.1200/JCO.2003.04.021 12560435 (Pubitemid 46606475)
20. A Di Leo D Gancberg D Larsimont M Tanner T Jarvinen G Rouas S Dolci JY Leroy M Paesmans J Isola MJ Piccart 2002 HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil Clin Cancer Res 8 1107 1116 1:CAS:528:DC%2BD38XksVSqu7s%3D 12006526
21. F Akiyama R Horii 2009 Therapeutic strategies for breast cancer based on histological type Breast Cancer 16 3 168 172 10.1007/s12282-009-0126-8 19479319
22. P Farmer H Bonnefoi V Becette M Tubiana-Hulin P Fumoleau D Larsimont G Macgrogan J Bergh D Cameron D Goldstein S Duss AL Nicoulaz C Brisken M Fiche M Delorenzi R Iggo 2005 Identification of molecular apocrine breast tumours by microarray analysis Oncogene 24 4660 4671 1:CAS:528:DC%2BD2MXlvVGhsLc%3D 10.1038/sj.onc.1208561 15897907 (Pubitemid 41032603)
23. T Sorlie R Tibshirani J Parker T Hastie JS Marron A Nobel S Deng H Johnsen R Pesich S Geisler J Demeter CM Perou PE Lønning PO Brown AL Børresen-Dale D Botstein 2003 Repeated observation of breast tumor subtypes in independent gene expression data sets Proc Natl Acad Sci USA 100 8418 8423 1:CAS:528:DC%2BD3sXlsFGntLk%3D 10.1073/pnas.0932692100 12829800 (Pubitemid 36842560)
24. LA Carey EC Dees L Sawyer L Gatti DT Moore F Collichio DW Ollila CI Sartor ML Graham CM Perou 2007 The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes Clin Cancer Res 13 2329 2334 1:CAS:528:DC%2BD2sXkt1enur0%3D 10.1158/1078-0432.CCR-06-1109 17438091 (Pubitemid 46698581)
25. CM Perou T Sørlie MB Eisen M van de Rijn SS Jeffrey CA Rees JR Pollack DT Ross H Johnsen LA Akslen O Fluge A Pergamenschikov C Williams SX Zhu PE Lønning AL Børresen-Dale PO Brown D Botstein 2000 Molecular portraits of human breast tumours Nature 406 747 752 1:CAS:528: DC%2BD3cXmt1CnsLw%3D 10.1038/35021093 10963602
26. Haagensen CD, Bodian C, Haagensen DE Jr. Breast carcinoma: risk and detection. Philadelphia: W.B. Saunders;1981.
27. A Goldhirsch WC Wood RD Gelber AS Coates B Thürlimann HJ Senn 10th St. Gallen Conference 2007 Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007 Ann Oncol 18 1133 1144 1:STN:280:DC%2BD2svlvVSkuw%3D%3D 10.1093/annonc/mdm271 17675394 (Pubitemid 47244357)
28. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology™ Breast Cancer V.I.2008.